O'hagan DT - Search Results

1

An investigation of the factors controlling the adsorption of protein antigens to anionic PLG microparticles.

Chesko J, Kazzaz J, Ugozzoli M, O'hagan DT, Singh M. Chesko J, et al. J Pharm Sci. 2005 Nov;94(11):2510-9. doi: 10.1002/jps.20472. J Pharm Sci. 2005. PMID: 16200615

2

The effect of CTAB concentration in cationic PLG microparticles on DNA adsorption and in vivo performance.

Singh M, Ugozzoli M, Briones M, Kazzaz J, Soenawan E, O'Hagan DT. Singh M, et al. Pharm Res. 2003 Feb;20(2):247-51. doi: 10.1023/a:1022327305369. Pharm Res. 2003. PMID: 12636163

3

Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B.

Singh M, Kazzaz J, Chesko J, Soenawan E, Ugozzoli M, Giuliani M, Pizza M, Rappouli R, O'Hagan DT. Singh M, et al. J Pharm Sci. 2004 Feb;93(2):273-82. doi: 10.1002/jps.10538. J Pharm Sci. 2004. PMID: 14705185

4

Charged polylactide co-glycolide microparticles as antigen delivery systems.

Singh M, Kazzaz J, Ugozzoli M, Chesko J, O'Hagan DT. Singh M, et al. Expert Opin Biol Ther. 2004 Apr;4(4):483-91. doi: 10.1517/14712598.4.4.483. Expert Opin Biol Ther. 2004. PMID: 15102598 Review.

5

Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not.

Singh M, Chesko J, Kazzaz J, Ugozzoli M, Kan E, Srivastava I, O'Hagan DT. Singh M, et al. Pharm Res. 2004 Dec;21(12):2148-52. doi: 10.1007/s11095-004-7666-6. Pharm Res. 2004. PMID: 15648244

6

A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens.

Singh M, Ugozzoli M, Kazzaz J, Chesko J, Soenawan E, Mannucci D, Titta F, Contorni M, Volpini G, Del Guidice G, O'Hagan DT. Singh M, et al. Vaccine. 2006 Mar 6;24(10):1680-6. doi: 10.1016/j.vaccine.2005.09.046. Epub 2005 Oct 6. Vaccine. 2006. PMID: 16300864

7

Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency.

Kazzaz J, Singh M, Ugozzoli M, Chesko J, Soenawan E, O'Hagan DT. Kazzaz J, et al. J Control Release. 2006 Feb 21;110(3):566-73. doi: 10.1016/j.jconrel.2005.10.010. Epub 2005 Dec 19. J Control Release. 2006. PMID: 16360956

8

Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems.

Singh M, Kazzaz J, Ugozzoli M, Malyala P, Chesko J, O'Hagan DT. Singh M, et al. Curr Drug Deliv. 2006 Jan;3(1):115-20. doi: 10.2174/156720106775197565. Curr Drug Deliv. 2006. PMID: 16472100 Review.

9

The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles.

Malyala P, Chesko J, Ugozzoli M, Goodsell A, Zhou F, Vajdy M, O'Hagan DT, Singh M. Malyala P, et al. J Pharm Sci. 2008 Mar;97(3):1155-64. doi: 10.1002/jps.21065. J Pharm Sci. 2008. PMID: 17683059

10

Characterization of antigens adsorbed to anionic PLG microparticles by XPS and TOF-SIMS.

Chesko J, Kazzaz J, Ugozzoli M, Singh M, O'Hagan DT, Madden C, Perkins M, Patel N. Chesko J, et al. J Pharm Sci. 2008 Apr;97(4):1443-53. doi: 10.1002/jps.21040. J Pharm Sci. 2008. PMID: 17724659

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

216 results

Search Page

Filters